Predictive Factors for Retreatment after Intravitreal Ranibizumab Injection to Treat Type 1 Retinopathy of Prematurity

Author:

Park Su Hwan,Byon Iksoo,Kwon Han Jo

Abstract

Purpose: To investigate predictive factors for retreatment after intravitreal ranibizumab injection as first-line treatment for retinopathy of prematurity (ROP).Methods: The medical records of consecutive infants diagnosed with type 1 ROP from 2013 to 2021 who received 0.2 mg intravitreal ranibizumab as their first treatments were retrospectively reviewed. Only eyes with severe ROP were included. Retreatment was performed if eyes again met the criteria for type 1 ROP or presented with stage 3 ROP and the plus sign. Factors around the time of first injection that predicted retreatment were assessed.Results: Intravitreal ranibizumab was injected into 44 eyes of 44 infants. The mean gestational age (GA) and body weight were 27.8 weeks and 1,046.6 g, respectively. Retreatment was required by 21 eyes (47.7%) at an average of 8.9 weeks after the first injection, thus at 37.2 weeks of mean postmenstrual age. The retreatment group exhibited a lower GA (<i>p</i> = 0.036), lower 1 minute (min) (<i>p</i> = 0.014) and 5 min (<i>p</i> = 0.029) Apgar scores, and more quadrants with plus signs (<i>p</i> = 0.044) before the first injections; they also had a longer period of oxygen requirement (<i>p</i> = 0.001), more loss of the plus sign (<i>p</i> = 0.014), and more ROP involution (<i>p</i> = 0.003) after the first injections. The risk of needing retreatment increased with a lower 1 min Apgar score (<i>p</i> = 0.010, odds ratio [OR] = 2.04) and later disappearance of the plus sign (<i>p</i> = 0.013, OR = 1.44) after the first injection.Conclusions: About half of patients with type 1 ROP may require retreatment 2 months after the first ranibizumab injection. Delayed loss of the plus sign increases the risk of retreatment; careful fundus examination is recommended after the first injection.

Funder

Pusan National University Hospital

Publisher

Korean Ophthalmological Society

Subject

Ophthalmology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3